Research in brief

Helicobacter pylori screening and gastric cancer incidence In a randomised trial, investigators in Taiwan assessed whether inviting individuals to undertake Helicobacter pylori stool antigen screening (HPSA) along with their regular biennial faecal immunochemical test (FIT) would reduce gastric cancer incidence and mortality compared with FIT alone. Unadjusted data showed no difference between the groups for gastric cancer incidence. [...]when data were adjusted post-hoc for differences in participation, length of follow-up, and baseline characteristics such as age and sex, the incidence of gastric cancer was lower in the HPSA plus FIT group than in the FIT alone group (adjusted relative risk 0·79, 95% CI 0·63–0·98; p=0·04).